Literature DB >> 3461929

[A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine].

Z Y Zhang, C H Hou, Y F Zhu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3461929

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN： 0578-1426


× No keyword cloud information.
  5 in total

Review 1.  Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-20

2.  Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.

Authors:  Stephan Philipp; Justyna Sosna; Johannes Plenge; Holger Kalthoff; Dieter Adam
Journal:  Cell Commun Signal       Date:  2015-04-29       Impact factor: 5.712

Review 3.  Homoharringtonine and omacetaxine for myeloid hematological malignancies.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2014-01-03       Impact factor: 17.388

4.  Enantiomeric Cephalotaxus alkaloids from seeds of Cephalotaxus oliveri.

Authors:  Guang-Xing Yu; Jing Wu; Bao-Bao Shi; Mei-Fen Bao; Xiang-Hai Cai
Journal:  Nat Prod Bioprospect       Date:  2022-07-01

Review 5.  Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Onco Targets Ther       Date:  2014-01-31       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.